Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda
详细信息 查看全文
- 作者：Betty Balikagala ; Toshihiro Mita ; Mie Ikeda ; Miki Sakurai…
- 关键词：In vivo selection ; pfkelch13 ; Artemether–lumefantrine ; Drug resistance ; Polymorphisms ; Plasmodium falciparum
- 刊名：Malaria Journal
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：16
- 期：1
- 全文大小：1520KB
- 刊物主题：Parasitology; Tropical Medicine; Infectious Diseases; Entomology; Microbiology; Public Health;
- 出版者：BioMed Central
- ISSN：1475-2875
- 卷排序：16
文摘
BackgroundIndividual drug treatment may select resistant parasites in the human body, a process termed in vivo selection. Some single nucleotide polymorphisms in Plasmodium falciparum chloroquine-resistance transporter (pfcrt) and multidrug resistance gene 1 (pfmdr1) genes have been reportedly selected after artemether–lumefantrine treatment. However, there is a paucity of data regarding in vivo selection of P. falciparum Kelch propeller domain (pfkelch13) polymorphisms, responsible for artemisinin-resistance in Asia, and six putative background mutations for artemisinin resistance; D193Y in ferredoxin, T484I in multiple resistance protein 2, V127M in apicoplast ribosomal protein S10, I356T in pfcrt, V1157L in protein phosphatase and C1484F in phosphoinositide-binding protein.